Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated:  12/31/1969
Geisinger Cancer Institute at Geisinger Health
mi
from
Danville, PA
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated: 12/31/1969
Geisinger Cancer Institute at Geisinger Health
mi
from
Danville, PA
Click here to add this to my saved trials
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated:  12/31/1969
Geisinger Hazleton Cancer Center
mi
from
Hazleton, PA
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated: 12/31/1969
Geisinger Hazleton Cancer Center
mi
from
Hazleton, PA
Click here to add this to my saved trials
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated:  12/31/1969
Geisinger Medical Group - Scenery Park
mi
from
State College, PA
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated: 12/31/1969
Geisinger Medical Group - Scenery Park
mi
from
State College, PA
Click here to add this to my saved trials
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated:  12/31/1969
Frank M. and Dorothea Henry Cancer Center at Geisinger Wyoming Valley Medical Center
mi
from
Wilkes-Barre, PA
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated: 12/31/1969
Frank M. and Dorothea Henry Cancer Center at Geisinger Wyoming Valley Medical Center
mi
from
Wilkes-Barre, PA
Click here to add this to my saved trials
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated:  12/31/1969
Mercy Hospital at Wilkes-Barre
mi
from
Wilkes-Barre, PA
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated: 12/31/1969
Mercy Hospital at Wilkes-Barre
mi
from
Wilkes-Barre, PA
Click here to add this to my saved trials
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated:  12/31/1969
Avera Cancer Institute
mi
from
Sioux Falls, SD
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated: 12/31/1969
Avera Cancer Institute
mi
from
Sioux Falls, SD
Click here to add this to my saved trials
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated:  12/31/1969
Medical X-Ray Center, PC
mi
from
Sioux Falls, SD
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated: 12/31/1969
Medical X-Ray Center, PC
mi
from
Sioux Falls, SD
Click here to add this to my saved trials
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated:  12/31/1969
Sanford Cancer Center at Sanford USD Medical Center
mi
from
Sioux Falls, SD
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated: 12/31/1969
Sanford Cancer Center at Sanford USD Medical Center
mi
from
Sioux Falls, SD
Click here to add this to my saved trials
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated:  12/31/1969
Fredericksburg Oncology, Incorporated
mi
from
Fredericksburg, VA
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated: 12/31/1969
Fredericksburg Oncology, Incorporated
mi
from
Fredericksburg, VA
Click here to add this to my saved trials
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated:  12/31/1969
Green Bay Oncology, Limited at St. Vincent Hospital Regional Cancer Center
mi
from
Green Bay, WI
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated: 12/31/1969
Green Bay Oncology, Limited at St. Vincent Hospital Regional Cancer Center
mi
from
Green Bay, WI
Click here to add this to my saved trials
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated:  12/31/1969
Green Bay Oncology, Limited at St. Mary's Hospital
mi
from
Green Bay, WI
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated: 12/31/1969
Green Bay Oncology, Limited at St. Mary's Hospital
mi
from
Green Bay, WI
Click here to add this to my saved trials
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated:  12/31/1969
St. Mary's Hospital Medical Center - Green Bay
mi
from
Green Bay, WI
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated: 12/31/1969
St. Mary's Hospital Medical Center - Green Bay
mi
from
Green Bay, WI
Click here to add this to my saved trials
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated:  12/31/1969
St. Vincent Hospital Regional Cancer Center
mi
from
Green Bay, WI
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated: 12/31/1969
St. Vincent Hospital Regional Cancer Center
mi
from
Green Bay, WI
Click here to add this to my saved trials
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated:  12/31/1969
Bay Area Cancer Care Center at Bay Area Medical Center
mi
from
Marinette, WI
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated: 12/31/1969
Bay Area Cancer Care Center at Bay Area Medical Center
mi
from
Marinette, WI
Click here to add this to my saved trials
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated:  12/31/1969
Green Bay Oncology, Limited - Oconto Falls
mi
from
Oconto Falls, WI
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated: 12/31/1969
Green Bay Oncology, Limited - Oconto Falls
mi
from
Oconto Falls, WI
Click here to add this to my saved trials
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated:  12/31/1969
Green Bay Oncology, Limited - Sturgeon Bay
mi
from
Sturgeon Bay, WI
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated: 12/31/1969
Green Bay Oncology, Limited - Sturgeon Bay
mi
from
Sturgeon Bay, WI
Click here to add this to my saved trials
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated:  12/31/1969
Welch Cancer Center at Sheridan Memorial Hospital
mi
from
Sheridan, WY
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated: 12/31/1969
Welch Cancer Center at Sheridan Memorial Hospital
mi
from
Sheridan, WY
Click here to add this to my saved trials
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated:  12/31/1969
Meeker County Memorial Hospital
mi
from
Litchfield, MN
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated: 12/31/1969
Meeker County Memorial Hospital
mi
from
Litchfield, MN
Click here to add this to my saved trials
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated:  12/31/1969
Regions Hospital - Cancer Care Center
mi
from
Saint Paul, MN
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor
Status: Enrolling
Updated: 12/31/1969
Regions Hospital - Cancer Care Center
mi
from
Saint Paul, MN
Click here to add this to my saved trials
HGS-ETR2 to Treat Children With Solid Tumors
A Phase I Trial of Monoclonal Antibody HGS-ETR2 (Lexatumumab) With or Without Interferon Gamma in Patients With Refractory Pediatric Solid Tumors
Status: Enrolling
Updated:  12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
HGS-ETR2 to Treat Children With Solid Tumors
A Phase I Trial of Monoclonal Antibody HGS-ETR2 (Lexatumumab) With or Without Interferon Gamma in Patients With Refractory Pediatric Solid Tumors
Status: Enrolling
Updated: 12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Effects of Pet Therapy on Pain in Cancer Patients
The Effect of Animal-Assisted Therapy on Distress in Oncology Patients Being Treated for Pain
Status: Enrolling
Updated:  12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Effects of Pet Therapy on Pain in Cancer Patients
The Effect of Animal-Assisted Therapy on Distress in Oncology Patients Being Treated for Pain
Status: Enrolling
Updated: 12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Neoadjuvant Accelerated Short Course Radiation Therapy With Proton Beam and Capecitabine for Resectable Pancreatic Cancer
Phase I/II of Neoadjuvant Accelerated Short Course Radiation Therapy With Proton Beam and Capecitabine for Resectable Pancreatic Cancer
Status: Enrolling
Updated:  12/31/1969
Dana-Farber Cancer Institute
mi
from
Boston, MA
Neoadjuvant Accelerated Short Course Radiation Therapy With Proton Beam and Capecitabine for Resectable Pancreatic Cancer
Phase I/II of Neoadjuvant Accelerated Short Course Radiation Therapy With Proton Beam and Capecitabine for Resectable Pancreatic Cancer
Status: Enrolling
Updated: 12/31/1969
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Neoadjuvant Accelerated Short Course Radiation Therapy With Proton Beam and Capecitabine for Resectable Pancreatic Cancer
Phase I/II of Neoadjuvant Accelerated Short Course Radiation Therapy With Proton Beam and Capecitabine for Resectable Pancreatic Cancer
Status: Enrolling
Updated:  12/31/1969
Massachusetts General Hospital
mi
from
Boston, MA
Neoadjuvant Accelerated Short Course Radiation Therapy With Proton Beam and Capecitabine for Resectable Pancreatic Cancer
Phase I/II of Neoadjuvant Accelerated Short Course Radiation Therapy With Proton Beam and Capecitabine for Resectable Pancreatic Cancer
Status: Enrolling
Updated: 12/31/1969
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
A Study of ThermoDox™ in Combination With Radiofrequency Ablation (RFA) in Primary and Metastatic Tumors of the Liver
A Phase I Dose Escalation Tolerability Study of ThermoDox™ (Thermally Sensitive Liposomal Doxorubicin) in Combination With Radiofrequency Ablation (RFA) of Primary and Metastatic Tumors of the Liver
Status: Enrolling
Updated:  12/31/1969
Northshore Hospital - Long Island Jewish Health System
mi
from
Manhasset, NY
A Study of ThermoDox™ in Combination With Radiofrequency Ablation (RFA) in Primary and Metastatic Tumors of the Liver
A Phase I Dose Escalation Tolerability Study of ThermoDox™ (Thermally Sensitive Liposomal Doxorubicin) in Combination With Radiofrequency Ablation (RFA) of Primary and Metastatic Tumors of the Liver
Status: Enrolling
Updated: 12/31/1969
Northshore Hospital - Long Island Jewish Health System
mi
from
Manhasset, NY
Click here to add this to my saved trials
Cancer Prevention and Treatment Demonstration for Ethnic and Racial Minorities
Cancer Prevention and Treatment Demonstration for Hispanic Medicare Eligible Beneficiaries - CMS
Status: Enrolling
Updated:  12/31/1969
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Cancer Prevention and Treatment Demonstration for Ethnic and Racial Minorities
Cancer Prevention and Treatment Demonstration for Hispanic Medicare Eligible Beneficiaries - CMS
Status: Enrolling
Updated: 12/31/1969
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy
Phase II Trial to Assess the Activity of Ketoconazole Plus Lenalidomide in Patients With Prostate Cancer Progressive After Androgen Deprivation
Status: Enrolling
Updated:  12/31/1969
University Suburban Health Center
mi
from
Cleveland, OH
Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy
Phase II Trial to Assess the Activity of Ketoconazole Plus Lenalidomide in Patients With Prostate Cancer Progressive After Androgen Deprivation
Status: Enrolling
Updated: 12/31/1969
University Suburban Health Center
mi
from
Cleveland, OH
Click here to add this to my saved trials
Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy
Phase II Trial to Assess the Activity of Ketoconazole Plus Lenalidomide in Patients With Prostate Cancer Progressive After Androgen Deprivation
Status: Enrolling
Updated:  12/31/1969
UHHS Chagrin Highlands Medical Center
mi
from
Cleveland, OH
Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy
Phase II Trial to Assess the Activity of Ketoconazole Plus Lenalidomide in Patients With Prostate Cancer Progressive After Androgen Deprivation
Status: Enrolling
Updated: 12/31/1969
UHHS Chagrin Highlands Medical Center
mi
from
Cleveland, OH
Click here to add this to my saved trials
Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy
Phase II Trial to Assess the Activity of Ketoconazole Plus Lenalidomide in Patients With Prostate Cancer Progressive After Androgen Deprivation
Status: Enrolling
Updated:  12/31/1969
UHHS Westlake Medical Center
mi
from
Cleveland, OH
Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy
Phase II Trial to Assess the Activity of Ketoconazole Plus Lenalidomide in Patients With Prostate Cancer Progressive After Androgen Deprivation
Status: Enrolling
Updated: 12/31/1969
UHHS Westlake Medical Center
mi
from
Cleveland, OH
Click here to add this to my saved trials
Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy
Phase II Trial to Assess the Activity of Ketoconazole Plus Lenalidomide in Patients With Prostate Cancer Progressive After Androgen Deprivation
Status: Enrolling
Updated:  12/31/1969
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center
mi
from
Cleveland, OH
Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy
Phase II Trial to Assess the Activity of Ketoconazole Plus Lenalidomide in Patients With Prostate Cancer Progressive After Androgen Deprivation
Status: Enrolling
Updated: 12/31/1969
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center
mi
from
Cleveland, OH
Click here to add this to my saved trials
Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy
Phase II Trial to Assess the Activity of Ketoconazole Plus Lenalidomide in Patients With Prostate Cancer Progressive After Androgen Deprivation
Status: Enrolling
Updated:  12/31/1969
Lake/University Seidman Cancer Center
mi
from
Cleveland, OH
Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy
Phase II Trial to Assess the Activity of Ketoconazole Plus Lenalidomide in Patients With Prostate Cancer Progressive After Androgen Deprivation
Status: Enrolling
Updated: 12/31/1969
Lake/University Seidman Cancer Center
mi
from
Cleveland, OH
Click here to add this to my saved trials
Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy
Phase II Trial to Assess the Activity of Ketoconazole Plus Lenalidomide in Patients With Prostate Cancer Progressive After Androgen Deprivation
Status: Enrolling
Updated:  12/31/1969
University Hospitals Cleveland Medical Center, Seidman Cancer Center, Case Comprehensive Cancer Center
mi
from
Cleveland, OH
Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy
Phase II Trial to Assess the Activity of Ketoconazole Plus Lenalidomide in Patients With Prostate Cancer Progressive After Androgen Deprivation
Status: Enrolling
Updated: 12/31/1969
University Hospitals Cleveland Medical Center, Seidman Cancer Center, Case Comprehensive Cancer Center
mi
from
Cleveland, OH
Click here to add this to my saved trials
Gemcitabine, Bevacizumab, and Abdominal Radiation Therapy in Treating Patients With Localized Pancreatic Cancer
A Phase II Trial of Weekly Gemcitabine Hydrochloride and Bevacizumab in Combination With Abdominal Radiation Therapy in Patients With Localized Pancreatic Cancer
Status: Enrolling
Updated:  12/31/1969
Northwestern University
mi
from
Chicago, IL
Gemcitabine, Bevacizumab, and Abdominal Radiation Therapy in Treating Patients With Localized Pancreatic Cancer
A Phase II Trial of Weekly Gemcitabine Hydrochloride and Bevacizumab in Combination With Abdominal Radiation Therapy in Patients With Localized Pancreatic Cancer
Status: Enrolling
Updated: 12/31/1969
Northwestern University
mi
from
Chicago, IL
Click here to add this to my saved trials
A Phase I Study of AC220 in Patients With Relapsed/Refractory Acute Myeloid Leukemia Regardless of FLT3 Status
Phase I Open-Label, Sequential Dose Escalation Study Investigating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AC220 When Administered Daily to Patients With Relapsed or Refractory Acute Myeloid Leukemia
Status: Enrolling
Updated:  12/31/1969
University of Alabama at Birmingham
mi
from
Birmingham, AL
A Phase I Study of AC220 in Patients With Relapsed/Refractory Acute Myeloid Leukemia Regardless of FLT3 Status
Phase I Open-Label, Sequential Dose Escalation Study Investigating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AC220 When Administered Daily to Patients With Relapsed or Refractory Acute Myeloid Leukemia
Status: Enrolling
Updated: 12/31/1969
University of Alabama at Birmingham
mi
from
Birmingham, AL
Click here to add this to my saved trials
A Phase I Study of AC220 in Patients With Relapsed/Refractory Acute Myeloid Leukemia Regardless of FLT3 Status
Phase I Open-Label, Sequential Dose Escalation Study Investigating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AC220 When Administered Daily to Patients With Relapsed or Refractory Acute Myeloid Leukemia
Status: Enrolling
Updated:  12/31/1969
Univ of Nebraska Med Ctr
mi
from
Omaha, NE
A Phase I Study of AC220 in Patients With Relapsed/Refractory Acute Myeloid Leukemia Regardless of FLT3 Status
Phase I Open-Label, Sequential Dose Escalation Study Investigating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AC220 When Administered Daily to Patients With Relapsed or Refractory Acute Myeloid Leukemia
Status: Enrolling
Updated: 12/31/1969
Univ of Nebraska Med Ctr
mi
from
Omaha, NE
Click here to add this to my saved trials
A Phase I Study of AC220 in Patients With Relapsed/Refractory Acute Myeloid Leukemia Regardless of FLT3 Status
Phase I Open-Label, Sequential Dose Escalation Study Investigating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AC220 When Administered Daily to Patients With Relapsed or Refractory Acute Myeloid Leukemia
Status: Enrolling
Updated:  12/31/1969
M.D. Anderson Cancer Center
mi
from
Houston, TX
A Phase I Study of AC220 in Patients With Relapsed/Refractory Acute Myeloid Leukemia Regardless of FLT3 Status
Phase I Open-Label, Sequential Dose Escalation Study Investigating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AC220 When Administered Daily to Patients With Relapsed or Refractory Acute Myeloid Leukemia
Status: Enrolling
Updated: 12/31/1969
M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
A Phase I Study of AC220 in Patients With Relapsed/Refractory Acute Myeloid Leukemia Regardless of FLT3 Status
Phase I Open-Label, Sequential Dose Escalation Study Investigating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AC220 When Administered Daily to Patients With Relapsed or Refractory Acute Myeloid Leukemia
Status: Enrolling
Updated:  12/31/1969
Chemotherapy and Immunotherapy Clinic
mi
from
T'Bilisi,
A Phase I Study of AC220 in Patients With Relapsed/Refractory Acute Myeloid Leukemia Regardless of FLT3 Status
Phase I Open-Label, Sequential Dose Escalation Study Investigating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AC220 When Administered Daily to Patients With Relapsed or Refractory Acute Myeloid Leukemia
Status: Enrolling
Updated: 12/31/1969
Chemotherapy and Immunotherapy Clinic
mi
from
T'Bilisi,
Click here to add this to my saved trials
AZD6244 (ARRY-142886) Solid Oral Dosage Formulation in Patients With Advanced Solid Malignancies
A Phase I, Open Label, Multi-centre Study to Assess the Safety, Tolerability and Pharmacokinetics of a Solid Oral Dosage Formulation (Capsule) of AZD6244 in Patients With Advanced Solid Malignancies
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Aurora, CO
AZD6244 (ARRY-142886) Solid Oral Dosage Formulation in Patients With Advanced Solid Malignancies
A Phase I, Open Label, Multi-centre Study to Assess the Safety, Tolerability and Pharmacokinetics of a Solid Oral Dosage Formulation (Capsule) of AZD6244 in Patients With Advanced Solid Malignancies
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Aurora, CO
Click here to add this to my saved trials
AZD6244 (ARRY-142886) Solid Oral Dosage Formulation in Patients With Advanced Solid Malignancies
A Phase I, Open Label, Multi-centre Study to Assess the Safety, Tolerability and Pharmacokinetics of a Solid Oral Dosage Formulation (Capsule) of AZD6244 in Patients With Advanced Solid Malignancies
Status: Enrolling
Updated:  12/31/1969
Research Site
mi
from
Nijmegen,
AZD6244 (ARRY-142886) Solid Oral Dosage Formulation in Patients With Advanced Solid Malignancies
A Phase I, Open Label, Multi-centre Study to Assess the Safety, Tolerability and Pharmacokinetics of a Solid Oral Dosage Formulation (Capsule) of AZD6244 in Patients With Advanced Solid Malignancies
Status: Enrolling
Updated: 12/31/1969
Research Site
mi
from
Nijmegen,
Click here to add this to my saved trials
Risk Communication Within Mexican-American Families
The Role of Family History and Culture in Communal Coping Within Mexican-American Families
Status: Enrolling
Updated:  12/31/1969
M.D. Anderson Cancer Center
mi
from
Houston, TX
Risk Communication Within Mexican-American Families
The Role of Family History and Culture in Communal Coping Within Mexican-American Families
Status: Enrolling
Updated: 12/31/1969
M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Vaccine Therapy and QS21 in Treating Patients With Metastatic Breast Cancer
Pilot Study of Immunization of High Risk Breast Cancer Patients With a Sialyl Lewisª -Keyhole Limpet Hemocyanin Conjugate Plus the Immunological Adjuvant QS-21
Status: Enrolling
Updated:  12/31/1969
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Vaccine Therapy and QS21 in Treating Patients With Metastatic Breast Cancer
Pilot Study of Immunization of High Risk Breast Cancer Patients With a Sialyl Lewisª -Keyhole Limpet Hemocyanin Conjugate Plus the Immunological Adjuvant QS-21
Status: Enrolling
Updated: 12/31/1969
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Effects of Mirtazapine on Appetite in Advanced Cancer Patients
Preliminary Study to Explore the Effects of Mirtazapine on Appetite in Advanced Cancer Patients
Status: Enrolling
Updated:  12/31/1969
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Effects of Mirtazapine on Appetite in Advanced Cancer Patients
Preliminary Study to Explore the Effects of Mirtazapine on Appetite in Advanced Cancer Patients
Status: Enrolling
Updated: 12/31/1969
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes
A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes
Status: Enrolling
Updated:  12/31/1969
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes
A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes
Status: Enrolling
Updated: 12/31/1969
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
TAC Versus TC for Adjuvant Breast Cancer
Phase III Trial of TC Versus TAC in HER2-Negative Early Stage Breast Cancer Patients
Status: Enrolling
Updated:  12/31/1969
Birmingham Hematology and Oncology
mi
from
Birmingham, AL
TAC Versus TC for Adjuvant Breast Cancer
Phase III Trial of TC Versus TAC in HER2-Negative Early Stage Breast Cancer Patients
Status: Enrolling
Updated: 12/31/1969
Birmingham Hematology and Oncology
mi
from
Birmingham, AL
Click here to add this to my saved trials
TAC Versus TC for Adjuvant Breast Cancer
Phase III Trial of TC Versus TAC in HER2-Negative Early Stage Breast Cancer Patients
Status: Enrolling
Updated:  12/31/1969
Hematology Oncology Associates
mi
from
Phoenix, AZ
TAC Versus TC for Adjuvant Breast Cancer
Phase III Trial of TC Versus TAC in HER2-Negative Early Stage Breast Cancer Patients
Status: Enrolling
Updated: 12/31/1969
Hematology Oncology Associates
mi
from
Phoenix, AZ
Click here to add this to my saved trials
TAC Versus TC for Adjuvant Breast Cancer
Phase III Trial of TC Versus TAC in HER2-Negative Early Stage Breast Cancer Patients
Status: Enrolling
Updated:  12/31/1969
Northern AZ Hematology Oncology Associates-AOA
mi
from
Sedona, AZ
TAC Versus TC for Adjuvant Breast Cancer
Phase III Trial of TC Versus TAC in HER2-Negative Early Stage Breast Cancer Patients
Status: Enrolling
Updated: 12/31/1969
Northern AZ Hematology Oncology Associates-AOA
mi
from
Sedona, AZ
Click here to add this to my saved trials
TAC Versus TC for Adjuvant Breast Cancer
Phase III Trial of TC Versus TAC in HER2-Negative Early Stage Breast Cancer Patients
Status: Enrolling
Updated:  12/31/1969
Arizona Oncology Associates, PC - HOPE
mi
from
Tucson, AZ
TAC Versus TC for Adjuvant Breast Cancer
Phase III Trial of TC Versus TAC in HER2-Negative Early Stage Breast Cancer Patients
Status: Enrolling
Updated: 12/31/1969
Arizona Oncology Associates, PC - HOPE
mi
from
Tucson, AZ
Click here to add this to my saved trials
TAC Versus TC for Adjuvant Breast Cancer
Phase III Trial of TC Versus TAC in HER2-Negative Early Stage Breast Cancer Patients
Status: Enrolling
Updated:  12/31/1969
Central Hematology/Oncology Medical Group, Inc.
mi
from
Alhambra, CA
TAC Versus TC for Adjuvant Breast Cancer
Phase III Trial of TC Versus TAC in HER2-Negative Early Stage Breast Cancer Patients
Status: Enrolling
Updated: 12/31/1969
Central Hematology/Oncology Medical Group, Inc.
mi
from
Alhambra, CA
Click here to add this to my saved trials
TAC Versus TC for Adjuvant Breast Cancer
Phase III Trial of TC Versus TAC in HER2-Negative Early Stage Breast Cancer Patients
Status: Enrolling
Updated:  12/31/1969
Comprehensive Blood and Cancer Center
mi
from
Bakersfield, CA
TAC Versus TC for Adjuvant Breast Cancer
Phase III Trial of TC Versus TAC in HER2-Negative Early Stage Breast Cancer Patients
Status: Enrolling
Updated: 12/31/1969
Comprehensive Blood and Cancer Center
mi
from
Bakersfield, CA
Click here to add this to my saved trials
TAC Versus TC for Adjuvant Breast Cancer
Phase III Trial of TC Versus TAC in HER2-Negative Early Stage Breast Cancer Patients
Status: Enrolling
Updated:  12/31/1969
St. Jude Hertiage Medical Group
mi
from
Fullerton, CA
TAC Versus TC for Adjuvant Breast Cancer
Phase III Trial of TC Versus TAC in HER2-Negative Early Stage Breast Cancer Patients
Status: Enrolling
Updated: 12/31/1969
St. Jude Hertiage Medical Group
mi
from
Fullerton, CA
Click here to add this to my saved trials
TAC Versus TC for Adjuvant Breast Cancer
Phase III Trial of TC Versus TAC in HER2-Negative Early Stage Breast Cancer Patients
Status: Enrolling
Updated:  12/31/1969
Wilshire Oncology Medical Group
mi
from
La Verne, CA
TAC Versus TC for Adjuvant Breast Cancer
Phase III Trial of TC Versus TAC in HER2-Negative Early Stage Breast Cancer Patients
Status: Enrolling
Updated: 12/31/1969
Wilshire Oncology Medical Group
mi
from
La Verne, CA
Click here to add this to my saved trials